In vivo aspirin supplementation inhibits nitric oxide consumption by human platelets

Blood

Volumn 106, Issue 8, 2005, Pages 2737-2743

  Williams, P Claire ^b   Coffey, Marcus J ^b   Coles, Barbara ^b   Sanchez, Stephanie ^b   Morrow, Jason D ^b   Cockcroft, John R ^b   Lewis, Malcolm J ^b   O'Donnell, Valerie B ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; MALE; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; THROMBOCYTE; THROMBOCYTE ACTIVATION;

EID: 27144481618     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-02-0664     Document Type: Article

References (34)

1. Albert J, Schedin U, Lindqvist M, Melcher A, Hjemdahl P, Frostell C. Blockade of endogenous nitric oxide production results in moderate hypertension, reducing sympathetic activity and shortening bleeding time in healthy volunteers Acta Anaesthesiol Scand. 1997;41:1104-1113.
2. Schafer A, Wiesmann F, Neubauer S, Eigenthaler M, Bauersachs J, Channon KM. Rapid regulation of platelet activation in vivo by nitric oxide. Circulation. 2004;109:1819-1822.
3. Andrews NP, Husain M, Dakak N, Quyyumi AA Platelet inhibitory effect of nitric oxide in the human coronary circulation: impact of endothelial dysfunction. J Am Coll Cardiol. 2001;37:510-516.
4. Oelze M, Mollnau H, Hoffmann N, et al. Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction. Circ Res. 2000;87:999-1005.
5. White CR, Brock TA, Chang LY, et al. Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci U S A. 1994;91:1044-1048.
6. O'Donnell VB, Coles B, Lewis MJ, Crews BC, Marnett LJ, Freeman BA Catalytic consumption of nitric oxide by prostaglandin H synthase-1 regulates platelet function. J Biol Chem. 2000;275:38239-38244.
7. O'Donnell VB, Taylor KB, Parthasarthy S, et al. 15-Lipoxygenase catalytically consumes nitric oxide and impairs activation of guanylate cyclase. J Biol Chem. 1999;274:20083-20091.
8. Coffey MJ, Natarajan R, Chumley PH, et al. Catalytic consumption of nitric oxide by leukocyte-type 12/15-lipoxygenase: inhibition of soluble guanylate cyclase activation in monocytes. Proc Natl Acad Sci U S A. 2001;98:8006-8011.
9. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Cyclooxygenase inhibition restored nitric oxide activity in essential hypertension. Hypertension. 1997;29:274-279.
10. Noon JP, Walker BR, Hand MF, Webb DJ. Impairment of forearm vasodilatation to acetylcholine in hypercholesterolemia is reversed by aspirin. Cardiovasc Res. 1998;38:480-484.
11. Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation. 1998;97:716-720.
12. Heitzer T, Ollmann I, Koke K, Meinertz T, Munzel T. Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease. Circulation. 2003;108:536-541.
13. Morrow JD, Minton TA. Improved assay for the quantification of 11-dehydrothromboxane B2 by gas chromatography-mass spectrometry. J Chromatography. 1993;612:179-185.
14. Pallapies D, Jirmann KU, Rademann J, et al. Effect of prostaglandin E2 and 3-morpholinosydnonimine (SIN-1) on arachidonic acid metabolism in fMLP-stimulated rat neutrophils and on thrombin-induced human platelet aggregation. Agents Actions. 1992;36:77-82.
15. Gassama-Diagne A, Simon MF, Chap H. Inhibition of platelet arachidonic acid liberation by endothelium-derived relaxing factor (EDRF) as studied with sin-1, a nitric oxide generating drug. Evidence for calcium-dependent and calcium-independent mechanisms. J Lipid Mediat. 1992;5:61-75.
16. Sane DC, Bielawska A, Greenberg CS, Hannun YA. Cyclic GMP analogs inhibit gamma thrombininduced arachidonic acid release in human platelets. Biochem Biophys Res Commun. 1989;165:708-714.
17. FitzGerald GA, Oates JA, Hawiger J, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983;71:676-688.
18. Rocca B, Secchiero P, Ciabattoni G, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A. 2002;99:7634-7639.
19. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance [letter]. Lancet. 1999;353:900.
20. Patrignani P, Sciulli MG, Manarini S, Santini G, Cerletti C, Evangelista V. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J Physiol Pharmacol. 1999;50:661-667.
21. Davi G, Averna M, Catalano I, et al. Increased thromboxane biosynthesis in type IIa hypercholesteroleamia. Circulation. 1992;85:1792-1798.
22. Mullershausen F, Russwurm M, Koesling D, Friebe A. In vivo reconstitution of the negative feedback in nitric oxide/cGMP signaling: role of phosphodiesterase type 5 phosphorylation. Mol Biol Cell. 2004;15:4023-4030.
23. Eikelboom JW, Hankey GJ. Aspirin resistance: a new independent predictor of vascular events. J Am Coll Cardiol. 2003;41:966-968.
24. Hennekens CH, Schror K, Weisman S, FitzGerald GA. Terms and conditions. Semantic complexity and aspirin resistance. Circulation. 2004;110:1706-1708.
25. Wong S, Appleberg M, Ward CM, Lewis DR. Aspirin resistance in cardiovascular disease: a review. Eur J Vasc Endovasc Surg. 2004;27:456-465.
26. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:960-965.
27. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 1994;12:2331-2336.
28. Webster SE, Payne DA, Jones CI, et al. Antiplatelet effect of aspirin is substantially reduced after administration of heparin during carotid endarterectomy. J Vasc Surg. 2004;40:463-468.
29. Payne DA, Jones CI, Hayes PD, Webster SE, Ross Naylor A, Goodall AH. Platelet inhibition by aspirin is diminished in patients during carotid surgery: a form of transient aspirin resistance? Thromb Haemost. 2004;92:89-96.
30. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650-1655.
31. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230-235.
32. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999;96:272-277.
33. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 1984;311:1206-1211.
34. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-1304.